243 related articles for article (PubMed ID: 33963686)
1. Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
Stodtmann S; Nader A; Polepally AR; Suleiman AA; Winzenborg I; Noertersheuser P; Ng J; Mostafa NM; Shebley M
Clin Transl Sci; 2021 Jul; 14(4):1611-1619. PubMed ID: 33963686
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
Abbas Suleiman A; Nader A; Winzenborg I; Beck D; Polepally AR; Ng J; Noertersheuser P; Mostafa NM
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):639-648. PubMed ID: 32945631
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
6. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
[TBL] [Abstract][Full Text] [Related]
7. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
8. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
9. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
Diamond MP; Carr B; Dmowski WP; Koltun W; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Mar; 21(3):363-71. PubMed ID: 23885105
[TBL] [Abstract][Full Text] [Related]
10. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.
Winzenborg I; Nader A; Polepally AR; Liu M; Degner J; Klein CE; Mostafa NM; Noertersheuser P; Ng J
Clin Pharmacokinet; 2018 Oct; 57(10):1295-1306. PubMed ID: 29476499
[TBL] [Abstract][Full Text] [Related]
13. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
[TBL] [Abstract][Full Text] [Related]
14. Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids.
Beck D; Winzenborg I; Gao W; Mostafa NM; Chiuve SE; Owens C; Shebley M
Br J Clin Pharmacol; 2022 Dec; 88(12):5257-5268. PubMed ID: 35695781
[TBL] [Abstract][Full Text] [Related]
15. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
[TBL] [Abstract][Full Text] [Related]
16. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
17. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
18. Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women.
Ng J; Chwalisz K; Carter DC; Klein CE
J Clin Endocrinol Metab; 2017 May; 102(5):1683-1691. PubMed ID: 28323948
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of elagolix in the treatment of endometriosis.
Perricos A; Wenzl R
Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
[TBL] [Abstract][Full Text] [Related]
20. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
Fantasia HC
Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
